Skip to main content

Abstract

Histamine modulators, more commonly referred to as antihistamines, have been commonly used in the USA for over half a century. Many of the dangerous side effects of these medications have been minimized due to the development of more advanced formulations with the removal of the more dangerous medications from the US market by the FDA. Knowledge of the potential side effect profiles of the antihistamines is necessary for any provider who is either prescribing or administering these medications. Those negative side effect profiles include the effects on the cardiac system and the central nervous system. In addition, providers must know the effects that occur with the extremes of age and during pregnancy. Potential metabolic effects are also important aspects that must be considered when dealing with antihistamines. Remarkably, only one of the antihistamines has been assigned a boxed warning by the FDA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Criado PR, Criado RFJ, Maruta CW, et al. Histamine, histamine receptors and antihistamines: new concepts. Braz Annals Dermatol. 2010;85(2):195–210.

    Article  Google Scholar 

  2. Jutel M, Blaser K, Akdis CA. Histamine in chronic allergic responses. J Invest Allergy Clin Immunol. 2005;15:1–8.

    CAS  Google Scholar 

  3. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489–98.

    Article  CAS  PubMed  Google Scholar 

  4. Monroe E, Daly A, Shalhoub R M.D. Appraisal of the validity of histamine-induced wheal and flare is used to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol. 1997;99(2):S789–806.

    Article  Google Scholar 

  5. Nicolas JM. The metabolic profile of second-generation antihistamines. Allergy. 2000;55 Suppl 60:46–52.

    Article  PubMed  Google Scholar 

  6. Lin S. Antihistamines. In: Sinatra R, Jahr J, Watkins-Pitchford J, editors. The essence of analgesia and analgesics. New York: Cambridge University Press; 2011. p. 391–6.

    Google Scholar 

  7. Davila I, Sastre J, Bartra J, del Cuvillo A, Jauregui I, Montoro J, et al. Effect of H1 antihistamines upon the cardiovascular system. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:13–23.

    PubMed  Google Scholar 

  8. Rumore MM, Schlichting DA. Analgesic effects of antihistaminics. Life Sci. 1985;36(5):403–16.

    Article  CAS  PubMed  Google Scholar 

  9. Kornhuber J, Parson CG, Hartnamm S, et al. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Transm Gen Sect. 1995;102(3):237–46.

    Article  CAS  PubMed  Google Scholar 

  10. Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc. 2007;55(8):1248–53.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Powell RJ, Du Toit GI, Siddique N, Leech SC, Dixon TA, Clark AT, British Society for Allergy and Clinical Immunology (BSACI), et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631–50.

    Article  CAS  PubMed  Google Scholar 

  12. Gill SK, O’Brien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci. 2009;54:1835–8.

    Article  CAS  PubMed  Google Scholar 

  13. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13 Suppl 3:18–26.

    Article  CAS  PubMed  Google Scholar 

  14. Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet. 1984;9(6):493–510.

    Article  CAS  PubMed  Google Scholar 

  15. U.S. Food and Drug Administration[Internet]. Postmarket drug safety information for patients and providers. Information for healthcare professionals – intravenous promethazine and severe tissue injury, including gangrene. (updated 09/16/2009). Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm182169.htm.

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Chemical Structures

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Yarborough, M., Johnson, J.G. (2015). Histamine Modulators. In: Kaye, A., Kaye, A., Urman, R. (eds) Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8948-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8948-1_22

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8947-4

  • Online ISBN: 978-1-4614-8948-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics